In stage II mismatch repair-proficient colon cancer with positive post-operative ctDNA, capecitabine ± oxaliplatin vs observation did not significantly improve 3-year DFS (61% vs 38%, HR 0.55, P=0.12). The trial closed early; only 2.9% of 1396 randomised were ctDNA-positive.
RCTn = 1,396
Folprecht et al. Chemotherapy for patients with circulating tumour DNA-positive, stage II colon cancer (CIRCULATE)-an AIO/ABCSG trial